Regeneron Pharmaceuticals, Inc. (LON:0R2M)

Market Cap	59.30B -3.0%
Revenue (ttm)	10.66B +1.0%
Net Income	3.35B +2.1%
EPS	30.82 +8.2%
Shares Out	n/a
PE Ratio	17.72
Forward PE	16.14
Dividend	2.68 (0.34%)
Ex-Dividend Date	Feb 20, 2026

Volume	195
Average Volume	621
Open	773.36
Previous Close	778.96
Day's Range	762.33 - 795.21
52-Week Range	477.01 - 820.00
Beta	0.39
RSI	52.57
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 15,410
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R2M

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD